Articles from Everest Medicines Limited

Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY(R) in Mainland China, Addressing Unmet Need in Moderately to Severely Active Ulcerative Colitis

By Everest Medicines Limited · Via ACN Newswire · March 11, 2026

Everest Medicines Shareholders Pass Resolutions Including Commercialization Service Agreement at EGM

By Everest Medicines Limited · Via ACN Newswire · February 25, 2026

Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis

By Everest Medicines Limited · Via ACN Newswire · February 6, 2026

Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013

By Everest Medicines Limited · Via ACN Newswire · February 4, 2026

Everest Medicines Unveils 2030 Strategy as Directors and Substantial Shareholder Buy Over HKD 38 Million of Shares

By Everest Medicines Limited · Via ACN Newswire · December 15, 2025

Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten

By Everest Medicines Limited · Via ACN Newswire · December 12, 2025

Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan

By Everest Medicines Limited · Via ACN Newswire · August 8, 2025

Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the Treatment for IgA Nephropathy

By Everest Medicines Limited · Via ACN Newswire · January 1, 2025

Everest Medicines Announces the First Prescription of VELSIPITY(R) in the Greater Bay Area

By Everest Medicines Limited · Via ACN Newswire · December 18, 2024

Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders

By Everest Medicines Limited · Via ACN Newswire · October 30, 2025

Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14

By Everest Medicines Limited · Via ACN Newswire · October 14, 2025

Everest Medicines Announces Publication of Etrasimod's Asian Multicenter Phase III ENLIGHT UC study (ES101002) Results in The Lancet Gastroenterology & Hepatology

By Everest Medicines Limited · Via ACN Newswire · October 9, 2025

Everest Medicines Announces 2025 Interim Results: 'Dual-Engine' Strategy Driving Strong Synergies Between Commercialization and R&D

By Everest Medicines Limited · Via ACN Newswire · September 1, 2025

Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC

By Everest Medicines Limited · Via ACN Newswire · August 15, 2025

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

By Everest Medicines Limited · Via ACN Newswire · December 16, 2024

Everest Medicines Announces the First Prescription of VELSIPITY(R) Issued in Macau

By Everest Medicines Limited · Via ACN Newswire · December 11, 2024

Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong

By Everest Medicines Limited · Via ACN Newswire · December 1, 2024

Everest Medicines' New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access

By Everest Medicines Limited · Via ACN Newswire · August 14, 2025

NEFECON(R) Receives NMPA Approval for Production Expansion in China,as Everest Medicines Accelerates Accessibility and Capacity Efforts

By Everest Medicines Limited · Via ACN Newswire · August 4, 2025

Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies

By Everest Medicines Limited · Via ACN Newswire · August 1, 2025

Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million

By Everest Medicines Limited · Via ACN Newswire · July 24, 2025

Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy

By Everest Medicines Limited · Via ACN Newswire · December 3, 2024